Exchange: NYSE·Updated 07:39 PM EDT
News
all
press releases
FDA Clears Blood Test To Detect Signs Of Alzheimer's Disease
FDA Clears Blood Test To Detect Signs Of Alzheimer's Disease Federal regulators have cleared a blood test aimed at detecting signs of Alzheimer's disease. The Food and Drug Administration cleared a blood test known as Elecsys pTau-217 for people aged at least 55 who have shown signs...
Zero Hedge
More News
Chemed (CHE) Up 1.7% Since Last Earnings Report: Can It Continue?
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference PR Newswire SECAUCUS, N.J., Aug. 25, 2026 SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in...
PR Newswire
Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com PR Newswire LONDON, Aug. 25, 2026 Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile...
PR Newswire
Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference PR Newswire SECAUCUS, N.J., Aug. 24, 2026 SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated...
PR Newswire
Beat the Market Like Zacks: Amgen, FirstCash, Delek in Focus
AMGN, FCFS and DK delivered strong gains, highlighting Zacks research successes across several model portfolios.
Zacks
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology PR Newswire SECAUCUS, N.J., Aug. 24, 2026 Test to join the company's expansive portfolio of...
PR Newswire
Is it the Right Time to Retain DGX Stock in Your Portfolio?
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Zacks
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks

Advertisement|Remove ads.